We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Perspective

Multiallergen-specific immunotherapy in polysensitized patients: where are we?

    Nerin Nadir Bahceciler

    * Author for correspondence

    Near East University, Faculty of Medicine, Division of Pediatric Allergy & Clinical Immunology, Nicosia, North Cyprus. .

    Search for more papers by this author

    Email the corresponding author at nerin74@gmail.com

    ,
    Nilufer Galip

    Near East University, Faculty of Medicine, Division of Pediatric Allergy & Clinical Immunology, Nicosia, North Cyprus

    Search for more papers by this author

    &
    Nazan Cobanoglu

    Near East University, Faculty of Medicine, Division of Pediatric Pulmonology, Nicosia, North Cyprus

    Search for more papers by this author

    Published Online:15 Feb 2013https://doi.org/10.2217/imt.12.161

    Abstract

    Allergen-specific immunotherapy administered by the subcutaneous route was introduced a century ago and has been shown to be effective in the management of allergic rhinitis and asthma. More recently, the sublingual administration of allergen extracts has become popular, especially in European countries, and has also demonstrated efficacy in respiratory allergic diseases. Both modes of allergen administration during immunotherapy have been shown not only to reduce symptoms and the need for medication, but also to prevent the development of additional sensitivities in monosensitized patients, as well as asthma development in patients with allergic rhinitis, with a long-lasting effect after the completion of several years of treatment. Almost all of the well-designed and double-blinded, placebo-controlled studies evaluated treatment with single-allergen extracts. Therefore, most meta-analyses published to date evaluated immunotherapy with single allergen or extracts containing several cross-reactive allergens. As a result, in general, multiallergen immunotherapy in polysensitized patients (mixture of noncross-reactive allergens) is not recommended owing to lack of evidence. Although some guidelines have recommended against the use of multiallergen mixtures, allergists commonly use mixtures to which the patient is sensitive with the rationale that effective immunotherapy should include all major sensitivities. Literature on this subject is scarce in spite of the widespread use worldwide. Here, this issue will be extensively discussed based on currently available literature and future perspectives will also be explored.

    Papers of special note have been highlighted as: ▪▪ of considerable interest

    References

    • 1  Noon L. Prophylactic inoculation against hay fever. Lancet1,1572–1573 (1911).
      Google Scholar
    • 2  Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet2,814–817 (1911).
      Google Scholar
    • 3  Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin. Ther.22,342–350 (2000).
      Medline CASGoogle Scholar
    • 4  Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst. Rev.1,CD001936 (2007).
      MedlineGoogle Scholar
    • 5  Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev.4,CD001186 (2003).
      MedlineGoogle Scholar
    • 6  Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy60,4–12 (2005).
      Medline CASGoogle Scholar
    • 7  Penagos M, Passalacqua G, Compalati E et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest133,599–609 (2008).
      Medline CASGoogle Scholar
    • 8  Des Roches A, Paradis L, Menardo JL, Bouges S, Daurés JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol.99,450–453 (1997).
      Medline CASGoogle Scholar
    • 9  Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy31,1392–1397 (2001).
      Medline CASGoogle Scholar
    • 10  Purello-D’Ambrosio F, Gangemi S, Merendino RA et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy31,1295–1302 (2001).
      MedlineGoogle Scholar
    • 11  Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol.109,251–256 (2002).
      MedlineGoogle Scholar
    • 12  Novembre E, Galli E, Landi F et al. Co-seasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.4,851–857 (2004).
      Google Scholar
    • 13  Ebner C, Kraft D, Ebner H. Booster immunotherapy (BIT). Allergy49,38–42 (1994).
      Medline CASGoogle Scholar
    • 14  Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med.341,468–475 (1999).
      Medline CASGoogle Scholar
    • 15  Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy33,206–210 (2003).
      Medline CASGoogle Scholar
    • 16  Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term (13-year) retrospective study in real life. Int. Arch. Allergy Immunol.142,70–78 (2007).
      Medline CASGoogle Scholar
    • 17  Bousquet PJ, Castelli C, Daures JP et al. Assessment of allergen sensitization in a general population-based survey (European Community Respiratory Health Survey I). Ann. Epidemiol.20,797–803 (2010).
      MedlineGoogle Scholar
    • 18  Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J. Allergy Clin. Immunol.116,377–383 (2005).
      MedlineGoogle Scholar
    • 19  Baatenburg de Jong A, Dikkeschei LD, Brand PL. Sensitization patterns to food and inhalant allergens in childhood: a comparison of non-sensitized, monosensitized, and polysensitized children. Pediatr. Allergy Immunol.22,166–171 (2011).
      MedlineGoogle Scholar
    • 20  Didier A, Chartier A, Demonet G. Specific sublingual immunotherapy: for which profiles of patients in practice? Midterm analysis of ODISSEE [observatory of the indication and management of respiratory allergies (rhinitis and/or conjunctivitis and/or allergic asthma) by specific sublingual immunotherapy]. Rev. Fr. Allergol.50,426–433 (2010).
      Google Scholar
    • 21  Craig TJ, King TS, Lemanske RF Jr et al. Aeroallergen sensitization correlates with PC(20) and exhaled nitric oxide in subjects with mild-to-moderate asthma. J. Allergy Clin. Immunol.121,671–677 (2008).
      Medline CASGoogle Scholar
    • 22  Ciprandi G, Cadario G, Di Gioacchino GM et al. Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc.31,227–231 (2010).
      MedlineGoogle Scholar
    • 23  Ciprandi G, Incorvaia C, Puccinelli P, Scurati S, Masieri S, Frati F. The POLISMAIL lesson: sublingual immunotherapy may be prescribed also in polysensitized patients. Int. J. Immunopathol. Pharmacol.23,637–640 (2010).
      Medline CASGoogle Scholar
    • 24  Malling HJ, Montagut A, Melac M et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin. Exp. Allergy39,387–393 (2009).
      Medline CASGoogle Scholar
    • 25  Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J. Allergy Clin. Immunol.91,709–722 (1993).
      Medline CASGoogle Scholar
    • 26  Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J. Allergy Clin. Immunol.123,763–769 (2009).
      Medline CASGoogle Scholar
    • 27  Calderón MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J. Allergy Clin. Immunol.129,929–934 (2012).
      Medline CASGoogle Scholar
    • 28  Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol.120,1338–1345 (2007).
      Medline CASGoogle Scholar
    • 29  Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.117,802–809 (2006).
      Medline CASGoogle Scholar
    • 30  Ciprandi G, Cadario G, Di Gioacchino M et al. Sublingual immunotherapy in polysensitized allergic patients with rhinitis and/or asthma: allergist choices and treatment efficacy. J. Biol Regul. Homeost. Agents23,165–171 (2009).
      Medline CASGoogle Scholar
    • 31  Ciprandi G, Cadario G, Valle C et al. Sublingual immunotherapy in polysensitized patients: effect on quality of life. J. Investig. Allergol. Clin. Immunol.20,274–279 (2010).
      Medline CASGoogle Scholar
    • 32  Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.117,319–325 (2006).
      Medline CASGoogle Scholar
    • 33  Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children – a 14-year study. Pediatrics42,793–802 (1968).
      Medline CASGoogle Scholar
    • 34  Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N. Engl. J. Med.273,675–679 (1965).
      Medline CASGoogle Scholar
    • 35  Franklin W, Lowell FC. Comparison of two dosages of ragweed extract in the treatment of pollenosis. JAMA201,915–917 (1967).
      Medline CASGoogle Scholar
    • 36  Bousquet J, Becker WM, Hejjaoui A et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J. Allergy Clin. Immunol.88,43–53 (1991).
      Medline CASGoogle Scholar
    • 37  Adkinson NF, Eggleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic children. N. Engl. J. Med.336,324–331 (1997).
      Medline CASGoogle Scholar
    • 38  Hedlin G, Wille S, Browaldh L et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J. Allergy Clin. Immunol.103,609–614 (1999).
      Medline CASGoogle Scholar
    • 39  Alvarez-Cuesta E, Aragoneses-Gilsanz E, Martin-Garcia C, Berges-Gimeno P, Gonzalez-Mancebo E, Cuesta-Herranz J. Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life. Clin. Exp. Allergy35,572–578 (2005).
      Medline CASGoogle Scholar
    • 40  Moncayo Coello CV, Rosas Vargas MA, del Rio Navarro BE, Lerma Ortiz L, Velásquez Armenta Y, Sienra Monge JJ. Quality of life in children with allergic rhinitis before and after being treated with specific immunotherapy (cases and controls). Rev. Alerg. Mex.50,170–175 (2003).
      MedlineGoogle Scholar
    • 41  Cirla AM, Cirla PE, Parmiani S, Pecora S. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two-year controlled study. Allergol. Immunopathol. (Madr.)31,31–43 (2003).
      Medline CASGoogle Scholar
    • 42  Marogna M, Spadolini I, Massolo A et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann. Allergy Asthma Immunol.98,274–280 (2007).
      Medline CASGoogle Scholar
    • 43  Amar SM, Harbeck RJ, Sills M, Silveira LJ, O’Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J. Allergy Clin. Immunol.124,150–156 (2009).
      Medline CASGoogle Scholar
    • 44  Keles S, Karakoc-Aydiner E, Ozen A et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J. Allergy Clin. Immunol.128,808–815 (2011).
      Medline CASGoogle Scholar
    • 45  Swamy RS, Reshamwala N, Hunter T et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J. Allergy Clin. Immunol.130,215–224 (2012).▪▪ First study demonstrating the development of long-term allergen-specific tolerance by epigenetic modifications of memory Tregs.
      Medline CASGoogle Scholar
    • 46  TePas EC, Hoyte EG, McIntire JJ, Umetsu DT. Clinical efficacy of microencapsulated Timothy grass pollen extract in grass-allergic individuals. Ann. Allergy Asthma Immunol.92,25–31 (2004).
      MedlineGoogle Scholar
    • 47  Nelson HS. Allergen immunotherapy: where is it now? J. Allergy Clin. Immunol.119(4),769–779 (2007).
      Medline CASGoogle Scholar
    • 48  Nelson HS. Specific immunotherapy with allergen mixes: what is the evidence? Curr. Opin Allergy Clin. Immunol.9(6),549–553 (2009).
      Medline CASGoogle Scholar
    • 49  Nelson HS, Iklé D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J. Allergy Clin. Immunol.98,382–388 (1996).
      Medline CASGoogle Scholar
    • 50  Grier TJ, LeFevre DM, Duncan EA, Esch RE. Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts. Ann. Allergy Asthma Immunol.99,151–160 (2007).
      Medline CASGoogle Scholar
    • 51  Esch ER. Allergen immunotherapy: what can and cannot be mixed? J. Allergy Clin. Immunol.122,659–660 (2008).
      MedlineGoogle Scholar
    • 52  Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann. Allergy Asthma Immunol.97,158–163 (2006).
      MedlineGoogle Scholar
    • 53  Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood114,3727–3735 (2009).
      Medline CASGoogle Scholar
    • 54  Limb SL,Brown KC, Wood RA, Eggleston PA, Hamilton RG, Adkinson NF Jr. Long term immunologic effects of broad-spectrum aeroallergen immunotherapy. Int. Arch. Allergy Immunol.140,245–251 (2006).
      Medline CASGoogle Scholar